Treatment and prognosis in antibasement membrane antibody-mediated nephritis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000032:analysis / Q000096:biosynthesis*; D001379:Azathioprine / Q000627:therapeutic use; D001485:Basement Membrane / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D006838:Hydrocarbons / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007251:Influenza, Human / Q000150:complications; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence; D012907:Smoking
D001323:Autoantibodies; D006680:HLA Antigens; D006838:Hydrocarbons; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone